EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates

Christophe Le Terrier iD, Patrice Nordmann, Mustafa Sadek iD, Laurent Poirel iD

Journal of Antimicrobial Chemotherapy · 03.05.2023 · 78 (5) · 1191-1194

DOI: 10.1093/jac/dkad061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 15.03.2023. Verfasst von Christophe Le Terrier und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Science and Medicine, Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, University of Fribourg, Fribourg, Switzerla…. Hauptthemen laut MEDLINE: Aztreonam, Escherichia coli. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Fribourg, Swiss National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Aztreonam/avibactam is one of the last therapeutic options for treating infections caused by NDM-like-producing Enterobacterales. However, PBP3-modified and NDM-producing Escherichia coli strains that co-produce CMY-42 have been shown to be resistant to this drug combination. The aim of our study was to assess the in vitro activity of cefepime/taniborbactam and cefepime/zidebactam against such aztreonam/avibactam-resistant E. coli strains.

Methods

MIC values of aztreonam, aztreonam/avibactam, cefepime, cefepime/taniborbactam, cefepime/zidebactam and zidebactam alone were determined for 28 clinical aztreonam/avibactam-resistant E. coli isolates. Those isolates produced either NDM-5 (n = 24), NDM-4 (n = 2) or NDM-1 (n = 2), and they all co-produced CMY-42 (n = 28). They all harboured a four amino acid insertion in PBP-3 (Tyr-Arg-Ile-Asn or Tyr-Arg-Ile-Lys).

Results

All strains were resistant to aztreonam/avibactam and cefepime, as expected. The resistance rate to cefepime/taniborbactam was 100%, with MIC50 and MIC90 being at 16 mg/L and 64 mg/L, respectively. Conversely, all strains were susceptible to cefepime/zidebactam, with both MIC50 and MIC90 at 0.25 mg/L. Notably, all strains showed low MICs for zidebactam alone, with MIC50 and MIC90 at 0.5 mg/L and 1 mg/L.

Conclusions

Our data highlighted the excellent in vitro performance of the newly developed β-lactam/β-lactamase inhibitor combination cefepime/zidebactam against aztreonam/avibactam-resistant E. coli strains, suggesting that this combination could be considered as an efficient therapeutic option in this context. Our study also highlights the cross-resistance between acquired resistance to aztreonam/avibactam and the cefepime/taniborbactam combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AztreonamEscherichia coliCefepimeAnti-Bacterial Agentsbeta-LactamasesCephalosporinsAzabicyclo Compoundsbeta-Lactamase InhibitorsMicrobial Sensitivity TestsPiperidinesCyclooctanesBorinic AcidsCarboxylic Acids

Substanzen

AztreonamCefepimeAnti-Bacterial Agentsbeta-LactamasesCephalosporinsAzabicyclo Compoundsbeta-Lactamase InhibitorszidebactamPiperidinesCyclooctanes

Autor:innen und Institutionen

  • Faculty of Science and Medicine, Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, University of Fribourg, Fribourg, Switzerland.
  • Division of Intensive Care Unit, University Hospitals of Geneva, Geneva, Switzerland.
  • Swiss National Reference Center for Emerging Antibiotic Resistance, Microbiology Unit, Fribourg, Switzerland.
  • Institute for Microbiology, University of Lausanne and University Hospital Center, Lausanne, Switzerland.
  • Department of Food Hygiene and Control, Faculty of Veterinary Medicine, South Valley University, Qena, Egypt.

ORCID-Profile: Christophe Le Terrier, Mustafa Sadek, Laurent Poirel

Förderung

  • University of Fribourg
  • Swiss National Science Foundation

Zitieren

APA

Le Terrier, C., Nordmann, P., Sadek, M., & Poirel, L. (2023). In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates. Journal of Antimicrobial Chemotherapy, 78(5), 1191-1194. https://doi.org/10.1093/jac/dkad061

Vancouver

Le Terrier C, Nordmann P, Sadek M, Poirel L. In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates. Journal of Antimicrobial Chemotherapy. 2023;78(5):1191-1194. doi:10.1093/jac/dkad061

BibTeX
@article{LeTerrier2023,
  author = {Le Terrier, Christophe and Nordmann, Patrice and Sadek, Mustafa and Poirel, Laurent},
  title = {In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  volume = {78},
  number = {5},
  pages = {1191--1194},
  doi = {10.1093/jac/dkad061}
}
Kostenlos starten →